BiologicsNeuro

InVivo Therapeutics to Present at 55th International Spinal Cord Society Annual Scientific Meeting

September 07, 2016

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President of Clinical Operations & Project Management, is scheduled to present at the 55th International Spinal Cord Society (ISCoS) Annual Scientific Meeting to be held September 14-16, 2016 in Vienna, Austria. Ms. Neff was invited to present along with several other leaders in the field of spinal cord injury clinical research on September 14 during the symposium titled “Clinical Trials Update for 2016.” The symposium, organized by the Spinal Cord Outcomes Partnership Endeavor (SCOPE), is intended to provide an update on current clinical research to foster communication between researchers and clinicians on advancements and challenges in clinical research.

“I am excited to share our encouraging progress to date and partake in the discussion on the challenges of conducting clinical studies in the spinal cord injury patient population,” Ms. Neff said.

For more information regarding the meeting, visit:https://www.iscosmeetings.org/

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com

Print Friendly, PDF & Email
Tags

Drue De Angelis

Drue is Managing Partner for The De Angelis Group, Executive Search firm exclusively for the Ortho & Spine industry.

Related Articles

Back to top button
Close